Cerevel Therapeutics Holdings, (CERE) Financials

CERE Assets vs Liabilities

DateAssetsLiabilities
Dec. 31, 2023 1.2 billion 569.6 million
Sept. 30, 2023 822.0 million 549.0 million
June 30, 2023 894.4 million 543.9 million
March 31, 2023 930.3 million 498.6 million

CERE Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2023 -98.3 million 25.2 million
Sept. 30, 2023 -73.1 million 17.1 million
June 30, 2023 -79.4 million 14.5 million
March 31, 2023 -95.3 million 12.6 million

CERE Net Income

No data available :(

CERE Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2023 991.0 million - 31.2 million
Sept. 30, 2023 676.9 million - 28.7 million
June 30, 2023 736.4 million - 29.5 million
March 31, 2023 827.0 million 336.0 million 30.4 million

CERE Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2023 174.6 million
Sept. 30, 2023 157.5 million
June 30, 2023 157.1 million
March 31, 2023 156.6 million

CERE Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2023 902000 97.1 million 42.4 million 1.5 million
Sept. 30, 2023 513000 85.3 million 26.1 million -
June 30, 2023 2.1 million 74.1 million 22.8 million -
March 31, 2023 336000 78.2 million 21.4 million -

CERE Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2023 - 1.5 million
Sept. 30, 2023 - 1.4 million
June 30, 2023 - 1.4 million
March 31, 2023 - 1.3 million

CERE

Price: $44.96

52 week price:
19.59
44.96

Earnings Per Share: -2.73 USD

P/E Ratio: -17.17

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 300700

Market Capitalization: 7.5 billion

Links: